针对肥胖的近期进展,重点关注TGF-β信号和迷走神经内置
Sahara John1, Krishanu Bhowmick1,2, Andrew Park1
1Institute for Bioelectronic Medicine, Divisions of Gastroenterology and Hepatology, Department of Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 11030, USA.
Bioelectronic medicine
|April 29, 2025
概括
肥胖和相关的肝脏疾病,如MASLD和MASH,影响了全球超过三分之一的人口. 本综述探讨了新疗法,包括GLP-1激动剂,TGF-β信号传递和迷走神经调节,用于这些疾病和相关的肝癌.
科学领域:
- 肝病学和代谢障碍 肝病和代谢障碍
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
背景情况:
- 肥胖,代谢功能障碍相关的性肝病 (MASLD) 和其严重形式的代谢功能障碍相关的性肝炎 (MASH) 影响了全球三分之一的人口.
- 这些疾病可能会发展为肝细胞癌 (HCC),这对全球健康构成重大挑战.
- 现有研究强调了转化生长因子-β (TGF-β) 信号和迷走神经调节在这些病理生理过程中的作用.
研究的目的:
- 审查当前的临床试验和肥胖和相关肝脏疾病的新疗法目标.
- 探索转化生长因子-β (TGF-β) 信号在脂肪生成,炎症和纤维化中的特定作用.
- 检查迷走神经调节策略在管理与肥胖相关的肝病和HCC的潜力.
主要方法:
- 对肥胖和相关肝脏疾病的临床试验的文献综述.
- 对TGF-β信号通路的新兴研究进行分析.
- 对神经/阴道调节策略及其应用研究的调查.
主要成果:
- 葡萄糖类1 (GLP-1) 激动剂和迷走神经刺激正在作为治疗选择推进.
- 确定TGF-β信号传递是参与MASLD/MASH和纤维化进展的关键途径.
- 迷你神经调节对腹调节,能量恒温和与肥胖相关的肝病的潜在治疗有希望.
结论:
- 针对TGF-β信号和迷走神经调节的新型治疗策略为治疗与肥胖相关的肝病和HCC提供了有希望的途径.
- 结合药理和神经调节干预的综合方法可能对管理这些复杂的疾病至关重要.
- 对这些途径的进一步研究对于开发有效的治疗方法来对抗日益增长的肥胖流行病及其肝脏并发症至关重要.
相关概念视频
01:30Regulation of Food Intake
144
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
144
01:40Hormonal Regulation
42.9K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
42.9K
01:24Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250